PTPaul Tannous

Paul Tannous

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Paul Tannous has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • ASD Diameter Indexed to Total Septal Length Outperforms Expert Opinion in Predicting Future Candidacy for Percutaneous ASD Closure

    by Lorraine James, Conor P. O’HAlloran, Bethan A. Lemley, Matthew Cornicelli, Jeremy Fox, David Winlaw, Alan Nugent, Paul Tannous

    Percutaneous device closure is an attractive alternative to surgical closure of secundum atrial septal defects (ASDs) for those with suitable anatomy and size. Early surgery (< 2 years of age) allows for a more feasible "mini sternotomy" technique, while device closure is more commonly performed at an older age. Thus, the ability to predict future device-closure candidacy before 2 years of age is needed. Secundum ASD closures after 3 years of age from 2012 to 2023 at a single center were reviewed (n = 54). "Early" echocardiograms (obtained at 12-24 months of age) and "pre-intervention" echocardiograms (the last echo obtained prior to closure and after 36 months of age) for each patient were independently reviewed by echocardiographers who performed standardized measurements. The catheterization team reviewed the same echocardiograms and made recommendations on device closure candidacy. Reviewers were blinded to the paired echocardiograms and eventual interventions. There was moderate agreement in perceived device candidacy by catheterization team consensus between early and pre-intervention echocardiogram (Cohen's Kappa = 0.56, p < 0.001). In a multivariable model, the ratio of maximum ASD diameter indexed to total septal length (ASD/TSL) between 1 and 2 years of age was strongly predictive of eventual perceived candidacy for device closure (Area Under the Curve = 0.92, sensitivity 89%, specificity 89% at the optimal threshold of 0.46) outperforming expert consensus (sensitivity 81%, specificity of 77%). Patients with ASD/TSL < 0.46 on early echocardiograms are likely to be considered device candidates later in life.

  • Open Access

    Hiding in Plain Sight: Pulmonary Vein Stenosis Following Pediatric Heart Transplantation

    by Conor P. O'HAlloran, Amanda Hauck, Anna Joong, Paul Tannous

    Background: Pulmonary vein stenosis (PVS) after pediatric heart transplantation (PHT) is an observed phenomenon with previously unknown incidence, risk factors, treatment, and outcome. Methods: This is a review of three recent publications describing PVS after PHT. Results: In total, 712 PHT recipients from four centers, over a combined 43 years, are reviewed. Thirty‐one new cases of PVS after PHT, in addition to six patients with preexisting PVS, are described. PVS diagnosis occurred in the first year after PHT for most patients. Left‐sided PVS were more than twice as common as right‐sided PVS. Nearly half (43%) experienced multivessel PVS. Major risk factors of PVS after PHT included younger age, history of congenital heart disease (CHD), and history of anomalous pulmonary venous return. The treatment of PVS after PHT varied, reflecting uncertainty in the management of PVS generally. With a median follow‐up of less than 3 years, 19% of patients with PVS after PHT died. Conclusions: PVS after PHT complicated approximately 4.4% of cases in these reports. PVS is more common after PHT in younger patients with a history of CHD. PVS is generally diagnosed in the first year after PHT. We recommend careful evaluation for PVS in the first year after PHT in patients with known risk factors.

  • Instantaneous Wave-Free Ratio Monitoring of an Anomalous Left Coronary During Self-Expanding Transcatheter Pulmonary Valve Implantation

    by Conor P. O’HAlloran, Kaitlin Swanson, Keegan Marz, Farshad Sedaghat-Yazdi, Paul Tannous

  • Open Access

    Hemodynamic Evaluation in Temporary Atrial Septal Defect Occlusion

    by Benjamin L. Magod, Yasmin Raza, Jeremy L. Fox, Kelley Chen, Marysa V. Leya, Paul Tannous, Daniel R. Schimmel

  • De Novo and Progressive Pulmonary Vein Stenosis Following Pediatric Heart Transplantation: A Multicenter Retrospective Study

    by Arene Butto, Conor O'HAlloran, James Kuo, Anna Joong, Amanda L. Hauck, Alan Nugent, William Mahle, Paul Tannous

    Background: Pulmonary vein stenosis (PVS) is a rare condition in which neointimal proliferation leads to venous and arterial hypertension. Little is known about PVS after heart transplant (HTx) in children. We sought to describe the characteristics and outcomes of children who develop PVS after HTx.Methods: We performed a retrospective review of patients ≤18 years old who underwent HTx at two HTx centers between April 2012 and October 2023. Patients with PVS were identified via database queries. Cardiac diagnosis, PVS location and extent, and outcomes were recorded.Results: Over 11.5 years, 422 patients underwent HTx across both centers. Nineteen patients with PVS (10 male) were identified, 15 with de novo PVS. Sixteen had underlying congenital heart disease (CHD), two with anomalous pulmonary venous return. PVS was diagnosed at a median of 2 months (range 2 weeks to 14 years) after HTx. At time of initial diagnosis, 13 patients had one‐vessel PVS. At final follow‐up, 7/19 (37%) had increases in the number of vessels involved. Six patients underwent surgery, and nine patients had stent or balloon angioplasty. Two patients were treated for pulmonary hypertension following PVS diagnosis. Three patients died from right heart failure secondary to PVS.Conclusions: This is the largest study to describe the characteristics of post‐HTx PVS in children. PVS occurs in 4.5% of HTx, and underlying CHD is a strong risk factor. Multiple vessels can be involved and may require catheter‐based or surgical intervention. Clinicians must be vigilant in monitoring the development of PVS in this population.


  • Interventions on residual lesions in patients with heterotaxy syndrome following orthotropic heart transplantation: A single‐center experience

    by Havisha Pedamallu, Conor P. O'HAlloran, Adam Morrison, Michael C. Monge, Defne A. Magnetta, Paul Tannous

    Background: Heterotaxy syndrome (HS) is a defect in lateralization which often results in complex intra and extracardiac abnormalities. Orthotropic heart transplantation (OHT) in HS involves intricate and individualized modifications to surgical technique. Post‐OHT outcomes are worse in patients with HS, however, the impact of post‐OHT residual lesions has not yet been characterized.Methods: Patients with HS who underwent OHT at Ann & Robert H. Lurie Children's Hospital of Chicago between January 2012 and June 2023 were identified. Patients were excluded if follow‐up data was not available due to follow up at a different institution of early mortality. Pre‐OHT clinical data, surgical data, and post‐OHT surgical and catheterization data were collected.Results: Two early mortalities were excluded from analysis, leaving 15 patients in the study cohort. Median age at OHT was 3.7 years (range: 0.7–15.4). Nine out of 15 patients were diagnosed with residual lesions requiring intervention at a median of 188 days post transplantation. All interventions on residual lesions occurred via catheterization. Overall mortality rate was 27% (4/15) with all deaths occurring in patients with residual lesions (4/9 patients, 44%). 83% (10/12) of lesions were diagnosed via catheterization, and 83% (10/12) of lesions of occurred in the first year after transplant.Conclusions: Patients with HS are at high risk for residual lesions after OHT, which may contribute to increased mortality. Comprehensive invasive diagnostics were required to diagnose residual lesions, which were all addressed percutaneously.

  • One children’s hospital planning and development process to adhere to the FDA recommendation that babies and young children undergo thyroid function testing after receiving an injection of iodine-containing contrast media for medical imaging

    by Dianna M. E. Bardo, Jill H. Samis, Jami L. Josefson, Marcelo R. Malakooti, Paul Tannous, Jeremy L. Fox, Jennifer Elhadary, Amanda Eichstaedt, Kenneth Gray, Agata Nytko, et al.

    The United States (US) Food and Drug Administration (FDA) has issued multiple statements and guidelines since 2015 on the topic of thyroid function testing in babies and children through 3 years old after receiving iodinated contrast media for medical imaging exams. In April 2023, the FDA adjusted this recommendation to target babies and young children younger than 4 years of age who have a history of prematurity, very low birth weight, or underlying conditions which affect thyroid gland function, largely in response to solid arguments from expert statements from the American College of Radiology (ACR) which is endorsed by the Society for Pediatric Radiology (SPR), Pediatric Endocrinology Society (PES), and the Society for Cardiovascular Angiography & Intervention (SCAI). Herein we describe our approach and development of a clinical care guideline along with the steps necessary for implementation of the plan including alterations in ordering exams requiring iodinated contrast media, automatic triggering of lab orders, reporting, and follow-up, to address the 2022 FDA guidance statement to monitor thyroid function in children after receiving iodinated contrast media. The newly implemented clinical care guideline at Ann and Robert H. Lurie Children’s Hospital of Chicago remains applicable following the 2023 updated recommendation from the FDA. We will track patients less than 3 months of age who undergo thyroid function testing following computed tomography (CT), interventional radiology, and cardiac catheterization exams for which an iodinated contrast media is administered as a clinical care quality initiative. Graphical Abstract


  • Open Access

    A Volume Challenge Reveals the Diagnosis of Pediatric Restrictive Cardiomyopathy

    by Elyssa Cohen, Conor P. O’halloran, Philip T. Thrush, T. Marsha Ma, Paul Tannous

    A healthy 11-year-old girl presented with exercise intolerance of unclear etiology, and her physical exam was notable for a 3/6 systolic ejection murmur at the left upper sternal border with radiation to the back. Extensive noninvasive workup consisted of ECG, transthoracic echocardiogram, and cardiac MRI/MRA, which were all nondiagnostic. She was ultimately referred for cardiac catheterization. Baseline invasive hemodynamics demonstrated a normal cardiac index and pulmonary vascular resistance but was notable for mildly elevated right and left end-diastolic pressures. A diagnosis remained elusive, so a 500 mL volume challenge was performed, which unmasked right and left ventricular waveform transformations to reveal the pathognomonic "square root sign " of restrictive cardiomyopathy with concordant RV/LV respirophasic variation. These findings and her clinical history allowed for the rare pediatric diagnosis of restrictive cardiomyopathy early in her clinical course, prior to the development of overt signs of pathologic myocardial remodeling, such as pulmonary hypertension and biatrial enlargement.